acmok@hhlaw.com
V-CARD
PHONE
+86.21.6122.3866
FAX
+86.21.6122.3899
|
|
Arthur
C.
Mok
Partner, Shanghai
Arthur Mok is the Managing Partner of Hogan & Hartson's Shanghai office. Arthur has extensive experience representing entrepreneurs, businesses, and investors in international transactional matters in Asia and the United States. Arthur focuses on private equity and venture capital financings, mergers and acquisitions, and complex commercial arrangements. He routinely advises clients in a wide range of industries, with a particular focus on life sciences and technology organizations with operations or business interests in China. Arthur previously practiced in the firm's Washington, D.C. office, where he advised clients on private equity and venture capital transactions.
REPRESENTATIVE EXPERIENCE
Advising a Beijing-based water equipment manufacturer in its pending Nasdaq Initial Public Offering (IPO).
Advising a Beijing-based printing equipment manufacturer in its pending New York Stock Exchange (NYSE) IPO.
Represented a Shanghai-based industrial biotech company in its $135 million preferred equity financing, one of the largest venture financings in China to date.
Represented a Shanxi-based coal energy company in its $47 million convertible bond financing.
Represented a Washington, D.C.-based private equity fund in its participation in the $25 million first round equity financing of a leading organic food company based in China, one of the first private equity financings in China's organic food industry.
Represented a Shanghai-based mobile advertising company in its $8 million second round preferred equity financing.
Represented a Beijing-based venture capital fund in its equity investment in a leading franchisor of retail commercial goods.
Represented a Sino-U.S.-based biotech company in its $9 million preferred equity financing by a leading Hong Kong based life sciences investment fund.
Represented a Shanghai-based industrial biotech company in its $52 million preferred equity financing, ranked as the largest venture capital financing in China for 2006.
Represented a Beijing-based private equity fund in its preferred equity investment in a Shanghai-based communications technology company.
Represented a Beijing-based software outsourcing company in its $10 million preferred equity financing by a leading Taipei-based venture fund.
Represented a large U.S.-based corporate strategic investor in numerous equity investments in early-to-expansion stage drug development companies.
Represented a Shanghai-based biotechnology company in the establishment of its drug discovery partnership with a leading global pharmaceutical company, recognized as the first discovery partnership between a China biotech and a major pharmaceutical company, and the establishment of its commercial alliance with a global consumer products company in relation to the development of new beauty care products.
Represented a Beijing-based medical device manufacturer in its research and development partnership with a leading Paris-based chemical products manufacturer.
Represented a Shanghai-based media broadcasting company in the structuring of a complex cross-border licensing and technical services agreement involving a large Korean media business.
Represented a Shanghai-based interactive gaming company in the structuring of its strategic partnerships with U.S. and China-based game developers.
Represented a Shanghai-based interactive entertainment company in a recapitalization transaction involving the buyout of the equity interests of its largest institutional investor.
Represented a San Francisco-based digital media company in its bid to acquire a Shanghai-based digital media company.
Represented a Hong Kong-based corporate strategic investor in its control equity investment in a U.S.-based medical device company.
Represented a U.S.-based medical diagnostic company in its acquisition of several complementary businesses.
Represented a NYSE-listed financial institution in its acquisition of a larger competing financial institution.
Represented the largest tire manufacturer in China in respect of product recall and related litigation matters in the United States.
Represented a large U.S.-based industrial water pump manufacturer in a commercial dispute submitted for arbitration in Beijing.
Represented the U.S. Trustee of a U.S.-based defense contractor subject to a Committee on Foreign Investments in the United States (CFIUS) divestiture order resulting from the control of its parent corporation by a Chinese government affiliated entity.
Published Works
03.01.2009
"Protection of Pharmaceutical IP in China." CPB Monthly
|
|
|